Literature DB >> 15711353

Neoadjuvant gonadotropin-releasing hormone therapy before surgery may improve the fertility index in undescended testes: a prospective randomized trial.

Christian Schwentner1, Josef Oswald, Alfons Kreczy, Andreas Lunacek, Georg Bartsch, Martina Deibl, Christian Radmayr.   

Abstract

PURPOSE: Subfertility is considered the principal consequence of cryptorchidism even after timely orchiopexy. Gonadotropin-releasing hormone (GNRH) treatment appears to improve fertility later in life by inducing germ cell maturation. In a prospectively randomized trial we investigated whether preoperative GNRH therapy improves the fertility index in primary cryptorchidism.
MATERIALS AND METHODS: A total of 42 boys 11 to 100 months old (median 33.5) with 63 undescended testes were prospectively assigned to 2 groups during a 6-month period. Patients were randomized to receive either orchiopexy alone (21 patients) or with neoadjuvant GNRH therapy (21) as a nasal spray for 4 weeks at 1.2 mg per day. In both groups testicular biopsies were performed at the time of orchiopexy and histopathological fertility index was determined.
RESULTS: Mean fertility index in the group treated with GNRH before surgery was significantly higher (1.05, SD +/- 0.71) compared to the group without hormonal stimulation (0.52, SD +/- 0.39, p <0.05). The subgroup of neoadjuvant stimulated boys younger than 24 months achieved the best results compared to the age matched boys without hormonal treatment.
CONCLUSIONS: Neoadjuvant GNRH treatment improves fertility index in prepubertal cryptorchidism. Consequently, preoperative hormone therapy should improve fertility in adulthood. Additionally, the nasal application is well tolerated, safe and already recommended in an adjuvant setting after orchiopexy. Maximum salvage of active germinal tissue is achieved by treating cryptorchidism before the end of the first year of life.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711353     DOI: 10.1097/01.ju.0000153562.07287.77

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

Review 1.  [Undescended testis: current treatment guidelines].

Authors:  B Haid
Journal:  Urologe A       Date:  2016-01       Impact factor: 0.639

2.  [Multimodal therapy of cryptorchism].

Authors:  A Rose; H Sperling; J Steffens; G Lümmen; B Hauffa; D Rohrmann; S Conrad; P Hoyer; H Rübben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

3.  [Late diagnosis of cryptorchidism].

Authors:  I Körner; C Neissner; J Steckermeier; W H Rösch
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

Review 4.  [Current and practice-relevant news from pediatric urology].

Authors:  R Stein; A Schröder; M Goepel
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

5.  Paediatrics: New cryptorchidism guidelines reach a consensus.

Authors:  Jorma Toppari
Journal:  Nat Rev Urol       Date:  2014-07-29       Impact factor: 14.432

6.  [Cryptorchidism and infertility from the perspective of interdisciplinary guidelines].

Authors:  M J Mathers; S Degener; S Roth
Journal:  Urologe A       Date:  2011-01       Impact factor: 0.639

Review 7.  [Cryptorchidism and fertility].

Authors:  I Rübben
Journal:  Urologe A       Date:  2016-07       Impact factor: 0.639

8.  [Undescended testis: aspects of treatment].

Authors:  I Körner; H Rübben
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

9.  Canadian Urological Association-Pediatric Urologists of Canada (CUA-PUC) guideline for the diagnosis, management, and followup of cryptorchidism.

Authors:  Luis H Braga; Armando J Lorenzo; Rodrigo L P Romao
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

10.  Effect of adjunctive hormonal therapy on testicular descent and spermatogenic function among children with cryptorchidism: a systematic review and meta-analysis.

Authors:  Kaiping Zhang; Yin Zhang; Min Chao
Journal:  Hormones (Athens)       Date:  2020-10-29       Impact factor: 2.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.